THE DETECTION OF SOMATIC MUTATIONS OF THYROTROPIN RECEPTOR GENE IN FINE NEEDLE BIOPSY SAMPLES FROM THYROID NODULES

A. SYRENICZ, 1G. KURZAWSKI, 2A. CIECHANOWICZ

Department of Endocrinology, Hypertension and Metabolic Diseases; 1Department of Genetics and Pathomorphology; 2Department of Clinical Biochemistry, Pomeranian Medical Academy, 71-455 Szczecin, Poland

Objective. To evaluate the detection possibility of TSH receptor gene mutation within the third cytoplasmic loop and the sixth transmembrane domain in the cytological material obtained by means of fine needle biopsy of autonomous and non–autonomous nodules.

Methods. The study has been carried out in 16 women with goitre showing no clinical signs of hyperthyroidism. According to the thyroid scintigraphy and serum level of thyrotropin (TSH) the patients were divided into two groups: 1. 6 patients with autonomous nodules; 2. 10 patients with non–autonomous nodules. Genomic DNA has been isolated from the cytological material and the peripheral blood nuclear cells in order to confirm possible somatic character of TSH receptor gene mutations. DNA has been amplified in polymerase chain reaction (PCR) with the use of a specific pair of primers. Purified PCR products have been subjected to further automatic sequencing.

Results. Among 6 autonomous nodules tested one heterozygotic somatic mutation of adenine for cytosine at 1804 nucleotide of TSH receptor gene was detected. This mutation resulted in the change of threonine (codon ACC) at 632 position of TSH receptor protein for proline (codon CCC). Among the non–autonomous nodules one heterozygotic somatic mutation of adenine for cytosine at 1870 nucleotide of receptor TSH gene has been detected. From this mutation followed the change of lysine (codon AAG) at 624 position of the polypeptide chain for glutamine (codon CAG) followed as a consequence.

Conclusions. We emphasize the validity of fine needle biopsy in the detection of somatic mutations in the TSH receptor gene. For the first time the somatic mutation in the TSH receptor gene in a non–autonomous nodule has been reported.

Key words: Thyroid nodules – TSH receptor – Somatic mutations – Fine needle biopsy

The occurrence of focal changes in the thyroid is an essential diagnostic and therapeutic problem. Palpable thyroid nodules are detectable in 4–7 % of the adults only (TAN and G HARI B 1997), while autopsy and ultrasound examinations reveal non–palpable focal changes in thyroid glands in approximately 50 % of the patients (MAZZAFERRI 1993). For proper diagnosis it is of crucial importance to estimate whether the nodule is benign or malignant using all possible diagnostic methods with fine needle biopsy as prior (MAZZAFERRI et al. 1988). Patients with neutral nodular goitre undergo both: surgery and regular treatment with the use of suppressive doses of thyroxine (G HARI B and MAZZAFERRI 1998). Theoretical basis for using thyroxine is based on widely recognised opinion of thyrotropin (TSH) involvement in growth regulation and function of follicular thyroid cells (VA S SART and DUMONT 1992). Thyrotropin binds to its receptor domain located on the outer side of thyrocyte cell membrane. As a result of ligand binding, the interaction of the receptor with heterotrimeric protein binding guanyl nucleotides (Gs) takes place which further results in the production of cAMP. Subsequently, cAMP stimulates the proliferation of thy-
rocytes including the synthesis and secretion of thy-
roid hormone. The existence of negative feedback
between TSH concentration and cAMP production
on the one hand and the process of intensified thyro-
cytes growth on the other is used in a regular treat-
ment of goitre with thyroxine.

The cause of goitre may be found among all those
factors which result in the thyroid enlargement, e.g.
iodine deficiency, antithyroid substances, immuno-
logical factors, the intrinsic thyrocyte growth poten-
tial and follicular replication rate within the same
gland being heterogenous (DERWAL 1996).

The new light on the pathogenesis was thrown by
PARMA et al. (1993) who detected somatic mutations
of TSH gene receptor responsible for constitutive ac-
tivation of this signal transduction system. These mu-
tations were identified in the third cytoplasmic loop
of the receptor. Another type of somatic mutation
was found in the same exon of TSH receptor gene
obtained by fine needle from hyperactive thyroid
adenomas (PORCELLI et al. 1994, 1995). These muta-
tions located within the VI transmembrane domain
of the TSH receptor result in its constitutive activa-
tion. The above data point to the fact that cAMP gen-
eration system may operate even in the absence of
TSH and of the changes of its concentration in se-
rum. So far, however, the presence of somatic muta-
tions of TSH gene receptor in non-autonomous thy-
roid nodules has not been detected.

Therefore, the aim of our study was to evaluate
the validity of aspiration fine needle biopsy for the
detection of somatic mutations of TSH gene recep-
tor in thyroid nodules and to estimate their frequen-
cy within the third cytoplasmic loop and the sixth
transmembrane domain in cytological material from
autonomous and non-autonomous thyroid nodules.

**Subjects and Methods**

**Patients.** The study was approved by the Ethical
Committee, Pomeranian Medical Academy. The first
group of patients consisted of 6 women (age range
24–29 years) with autonomous nodules classified as
hot nodules by scintigraphy (Tc99m) and decreased
TSH level by ultrasensitive IRMA assay (<0.3 mU/l).
The second group consisted of 10 women (age range
27–49 years) with scintigraphically warm (6 patients)
or cold nodules (4 patients) and normal TSH level
(0.3–5.6 mU/l). The samples for genomic DNA iso-
ation were obtained by fine needle biopsy (FNB)
and the histological examination of that also showed
benign character of nodular tissue in all cases.

**DNA isolation.** In each patient, the genomic DNA
was isolated from the cytological material obtained
from thyroid nodules and from peripheral blood cells.
Cytological material from FNB was placed in a
sterile test tube and preserved at −20°C for further
analysis. Peripheral blood nuclear cells (PBNC) were
obtained by concentration gradient (Gradisol L, Pol-
fa, Kutno) centrifugation of 10 ml venous blood tak-
en in EDTA. Genomic DNA from FNB and PBNC
was isolated using SDS-protease K method and
subsequent phenol extraction (SAMBROOK et al. 1989)
and placed in 18 and 200 µl of TE buffer, respec-
tively.

**Detection of the TSH receptor gene mutations
in thyroid nodules.** The TSH cDNA was amplified
in PCR with oligonucleotides: 5’-ACCGAGAC-
CCCTCTTGCTCT-3’ (bases: 1820 –1839) as
a sense primer (TSHR–D) and 5’-AGTTGCTAA-
CAGTGATGAGGCT-3’ (bases 2052 – 2075) as
an antisense primer (TSHR–E) (PORCELLINI  et al.
1994). The product of amplification with this pair
of primers was a segment (256 bp in length) of TSH-
R gene sequence from the second to third extracy-
toplasmic loop comprising the third intracytoplasm-
ic loop and the transmembrane domain (NAGAYA-
MA et al. 1989). DNA samples (5 µl from FNB or
200 ng from PBNC) were amplified in the solution
of 100 µl final volume containing 30 pM of each
primer, 2.5 mM of the deoxyribonucleotide (dATP,
dTTP, dCTP, dGTP; Promega), 50 mM KCl, 20 mM
Tris–HCl (pH 8.4), 1.5 mM MgCl2, 10 mg/ml of
nuclease free bovine serum albumin and 2.5 units
Taq DNA polymerase (Boehringer, Mannheim). The
thermal profile used on a Perkin Elmer/Cetus ther-
mal cycler consisted of an initial denaturation at
94°C for 3 min followed by denaturation at 94°C
for 30 sec, annealing for 1 min at 60°C and exten-
sion at 72°C for 1 min for 38 cycles for FNB-DNA
or 35 cycles for PBNC-DNA. After PCR, 10 µl loading
buffer (40 % sacharose, 0.25 % bromphenol
blue and xylene cyanol) was added to each sample,
the amplification products being then checked for
the predicted sizes and visualized by electrophore-
sis in 2 % agarose gel stained with ethidium bro-
SOMATIC MUTATIONS OF TSH RECEPTOR GENE

Results

The amount of genomic DNA obtained by FNB from thyroid nodule of each patient was sufficient for further examination using PCR method (Fig. 1). For each patient the same fragment of TSH receptor gene was also amplified by PCR using genomic DNA isolated from PBNC as a template.

By sequencing of both PCR products only in thyroid cells the heterozygous mutation of adenine for cytosine at 1894 nucleotide of TSH receptor gene has been found in one out of 6 patients with autonomous nodules only. As a consequence of such mutation, threonine (codon ACC) at 632 position of TSH-R polypeptide chain has been changed for proline (codon CCC) (Fig. 2).

In one out of 6 patients with non autonomous nodules the heterozygous mutation of adenine into cytosine at 1870 nucleotide of TSH receptor gene has been detected. The change of lysine (codon AAG) at 624 position of TSH receptor protein for glutamine (codon CAG) followed from such mutation (Fig. 3). Both mutations have been of somatic character since they occured in DNA of thyroid cells and have not been detected in PBNC-DNA (Fig. 2 and 3).

Discussion

First reports about hyperfunctioning thyroid nodules with somatic mutations of TSH receptor gene resulting in the constitutive activation of transduction system were reported by Parma et al. (1993). Such mutations were found in 3 out of 11 hyperfunctioning adenomas in the third cytoplasmic loop of the TSH receptor gene which concerned T to C transition in two cases resulting in the replacement of aspartic acid by glycine at position 619, and in one case in contiguous base substitution GC to TA which resulted in the replacement of alanine 623 by isoleucine. In the same exon of TSH receptor gene Porcellini et al. (1994) found another type of somatic mutation leading to its constitutive activation. Those mutations referred to 3 codons of three ami-
SOMATIC MUTATIONS OF TSH RECEPTOR GENE

In the sixth transmembrane domain, no acids resulted from the following changes: 1. phenylalanine to cysteine at position 631 of the TSH-R chain, 2. threonine to isoleucine at 632 position (resulting from G to A transition), 3. aspartic acid to glutamic acid (C to A transition) or tyrosine (G to A transition) at 633 position of the chain. So far, somatic mutations have been found in 7 out of 11 hyperfunctioning nodules (three at 632 and 633 positions and one at 631 position of the TSH-R sequence).

Further studies of toxic nodules not only confirmed the frequent occurrence of somatic mutation of the TSH receptor gene in areas described above, but also revealed their presence in other positions of the TSH–R chain. PARMA et al. (1995) reported somatic mutations in 9 out of 11 toxic adenomas and described two new locations in the first and second extracytoplasmic receptor loop at 486 position (isoleucine for phenylalanine) and at 568 position (change of isoleucine for threonine). HOLZAPFEL et al. (1997) described somatic mutations in 3 out of 6 toxic adenomas and found further new location at 630 position (isoleucine for leucine). PARMA et al. (1997) found 27 (82 %) mutations among 33 autonomous nodules including two new mutations: at 629 position (leucine for phenylalanine) and the deletion of 12 bases (removal of the 658-661 codons of C-terminal part of the third extracytoplasmic loop). FUEHRER et al. (1997) reported 15 somatic mutations (48 %) out of 31 toxic adenomas including two new changes at 656 position (valine for phenylalanine) and the deletion of 27 bases of the third intracytoplasmic loop (loss of 9 amino acids – codons from 613 to 621). TONACCHERA et al. (1998) showed that among patients with toxic nodular goitre mutations occurred in 13 out of 17 toxic nodules (76 %) including one at 639 position (proline for serine) which was described for the first time.

However, there are also some reports about substantially lower frequency or even their total absence of mutations in autonomous thyroid nodules. Thus, RUSSO et al. (1995) found them in only 8 % (3/37),
Takeshita et al. (1997) in only 2 % (1/45) and Pin- 
Ducciu et al. (1998) found no somatic mutations in 
15 toxic adenomas.

In may be concluded that so far 27 somatic muta-
tions of the TSH receptor gene in 12 different chain 
positions have been described, whilst some locations 
are preferred, especially at sixth transmembrane seg-
ment, in which 44 % of mutations described so far 
are localised (Parma et al. 1997). In our study we 
found one mutation at 632 position, described earli-
er, out of 6 autonomous nodules (17 %). We have 
found, however, the change of threonine for proline 
and not for isoleucine as reported earlier by Porcel-
lini (1994). The reasons for such diverse frequency 
ocurrence of somatic mutations in the TSH recep-
tor gene in autonomous nodules can be sought in 
ethnic differences (more often in Caucasians then in 
Japanese), methodological (investigation of a part of 
exon 10 or application of methods less sensitive then 
sequencing) and geographic differences connected 
with the access to iodine (mutations are described 
mostly in the areas with iodine deficiency) (Takesh-
ita et al. 1995; Parma et. al. 1997; Tonacchera et al. 
1998). 

As far as we are aware, the presence of TSH-R 
gene mutations in non-autonomous thyroid nodules 
has not been described yet. Among 10 of our pa-
tients with such nodules there was only one case of 
heterozygous mutation at 624 position of the TSH 
receptor with a consecuitive change of lysine for 
glutamine. In addition, it should be emphasized that 
the mutation at 624 position has not yet been de-
scribed. There are rare cases in the literature con-
cerning mild non-autonomous nodules in which so-
matic mutations of the TSH receptor gene have been 
described. Thus, Matsuo et al.(1993) tested 20 mild 
nodules from neutral multinodular goitre and 37 fol-
licular adenomas, however poor clinical characteris-
tics and the use of a less sensitive SSCP (Single 
Strand Conformational Polymorphism) method does 
not allow any unambiguous conclusions. Similar 
conclusions may be drawn by Esapa et al. (1997) who 
examined 66 mild thyroid nodules.

We cannot yet ascertain that the mutation found 
in our study led to the constitutive activation of the 
receptor with the consecuitive overproduction of 
cAMP, because in order to confirm such phenome-
on the cAMP concentration should have been mea-
sured in basal conditions and after the TSH stimula-
tion of mutated receptor-transfected COS cells as 
described by Porcellini et al. (1997). Second muta-
tion in our material at 632 position concerning au-
tonomous nodule is surely of constitutive character, 
which was confirmed by other authors using the in 
vitro COS model (Porcellini et al. 1994, Fuehrer et 
al. 1997).

The mutations found in our study were of somatic 
character, since we did not notice any changes of TSH 
receptor chain sequence in genomic DNA isolated 
from peripheral blood nuclear cells. Other authors 
also confirmed somatic character of the mutation 
(Porcellini et al. 1994; Parma et. al. 1993). If the 
fine needle biopsy is used for mutation search, con-
firmation of somatic character of the change using 
PBNC-DNA as the template for PCR may be 
achieved by means of a lower number of punctures 
and their restriction only to nodular area without any 
biopsy of extra-nodular tissue. The amount of DNA 
obtained from fine needle aspiration is sufficient to 
molecular analysis with the use of PCR and subse-
quint automatic sequencing. Good quality PCR prod-
ucts visualised in agarose gels and the sequencing 
results confirm the opinion thoroughly. Thus, the use 
of FNB can be of great importance in early detec-
tion of thyroid nodules leading finally to thyrotoxi-
cosis and can also enable further proper treatment.

In natural development of toxic nodular goitre, 
thyrocytes diversity in reference to their inner po-
tential growth, the activity of iodine transportation 
and thyroid peroxidase seem to be of main impor-
tance (Derwahl 1996; Studer et al. 1995). Thus, ir-
respective of the clonal nature of the nodule (mono-
clonal or polyclonal) it can be either hot or even cold. 
Since the proliferation rate is higher within the nod-
ule than in extranodular tissue, mutations are more 
frequent in the first cases (Derwahl 1996). It seems 
that the mutation of TSH receptor gene or other genes 
in signal transduction cascade could be of major 
importance in the stimulation of hyperfunction of 
the nodule, contrary to previous opinion claiming 
its primary role in tumorgenesis process (Derwahl 
1996). However, experimental in vitro research defi-
nitely showed that the somatic mutations of the TSH 
receptor gene resulted in its activation followed by 
the increase of cAMP concentration and subsequent 
stimulation of growth, differentiation and thyrocytes
function (VASART and DUMONT 1992). The presence of mutations in neutral nodules and the possibility of their identification by molecular analysis in FNB material can partially explain the resistance of some nodules to the treatment with suppressive thyroxine doses both for nodules which are neutral per se and for nodules which are only an intermediate stage in the development of toxic nodule. The available data (MORITA et al. 1989; CELANI 1993) show that only 30% of neutral nodules are prone to 50% volume reduction as a reaction to thyroxine administration. The mutations of the TSH receptor gene cannot be the only cause of treatment resistance; other mutations of oncogenes ras and gsp which are believed to be responsible for thyroid tumorigenesis should also be taken into account (KOPP et al. 1994). MATSUO et al. (1993) and ESAPA et al. (1997) showed the presence of single mutations of alpha Gs protein chain in neutral thyroid nodules.

In may be concluded that the FNB of thyroid nodules followed by molecular analysis of thyroid DNA is very useful in the search for somatic mutations of the TSH receptor gene. Therefore, the detection of TSH-R gene mutation causing the constitutive activation of signal transduction cascade may predict the resistance for suppressive thyroxine treatment. In addition, it can be helpful in the individual choice-therapy of neutral nodular goitre.

Acknowledgements

This study was supported by the Polish KBN Research Grant 4 P05B 065 11.

References

CELANI MF: Levothyroxine suppressive therapy in the medical management of nontoxic benign multinodular goiter. Exp Clin Endocrinol 101, 326-332, 1993
MATSUO K, FRIEDMAN E, GEJMAN PV, FAGIN JA: The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumors: structural studies of the TSH-R and the α-subunit of Gs in human thyroid neoplasms. J Clin Endocrinol Metab 76, 1446-1451, 1993
PARMA J, VAN SANDE J, SWILSENS S, TONACCHERA M, DUMONT J, VASSART G: Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca²⁺ cascades. Mol Endocrinol 9, 725-733, 1995
SOMATIC MUTATIONS OF TSH RECEPTOR GENE

JE, VASSART G: Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gsα genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metab 82, 2695-2701, 1997


PORCELLINI A, CIULLO I, PANNAIN S, FENZI G, AVVEDIMENTO E: Somatic mutations in the VI transmembrane segment of the thyrotropin receptor constitutively activate cAMP signaling in thyroid hyperfunctioning adenomas. Oncogene 11, 1089-1093, 1995


STUER H, PETER HJ, GEBERER H: Natural heterogeneity of thyroid cells: the basis for understanding thyroid function and nodular goiter growth. Endocrine Rev 10, 125-135, 1995


Corresponding author: Anhelli Syrenicz M.D.
Department of Endocrinology, Hypertension and Metabolic Diseases PAM
ul. Arkonska 4
71 – 455 Szczecin, Poland
Phone: 0048 91 4541468
Fax: 0048 91 4541916

Accepted: June 15, 1999
This is an excellent result of the giant project to bring together all present knowledge on diabetes presented by 188 outstanding experts and cut into more than 100 subject headings. The topics discussed in this king size manual include a broad spectrum of aspects from the molecular genetics, morphology, physiology, molecular basis of insulin action and immunopathogenesis, to the diagnosis, epidemiology, dietary management, drug treatment, implantable pumps, islet transplantation, glucose sensors, self monitoring (blood glucose, glycated hemoglobin, lipids), computer-assisted education of diabetic patient, special problems in management (brittle diabetes, childhood, pregnancy, aging), acute disturbances (hypoglycemia, ketoacidosis, infections, surgery, vascular events), chronic microvascular (nephropathy, retinopathy, peripheral neuropathy etc.) and macrovascular complications (coronary heart disease, clotting disorders, hypertension), diabetic foot and public health problems (organisation of care in various continents, economics of diabetes, social rights, primary prevention.

At the same time, such broad spectrum of topics defines the broad spectrum of the readers and professions (physicians of all medical fields, social workers, economists, biochemists, pharmacologists etc.) which may benefit from this diabetes bible. This comprehensive work, in addition to excellent and valuable scientific and medical information, presents up to date references and high quality of technical arrangements including up to additional 300 pages of indexes facilitating to find any subtopic on advancing broad field of diabetes.

Pavel Langer